Joint National Committee, nuevamente la guía de hipertensión arterial más polémica
Keywords:
Eighth Joint National CommitteeAbstract
Al igual que sucedió en el 2003 , en el 2013 se publicaron casi simultáneamente varias Guías de Hipertensión Arterial (HTA) . Nuevamente hay diferencias entre ellas y es la del Eighth Joint National Committee (JNC8) la más polémica.
Las directrices emitidas por el Joint National Committee han sido históricamente la de más influencia internacional, por esta razón consideramos oportuno reflexionar sobre el tema.
ABSTRACT
As happened in 2003, in 2013 they were published almost simultaneously several guides Hypertension (HTA). Again there are differences between them and is the Eighth Joint National Committee (JNC8) the most controversial.
The guidelines issued by the Joint National Committee have historically been the most international influence, therefore consider it appropriate to reflect on the issue.
References
Morales Salinas A. Guías de hipertensión arterial: Novedad y polémica. Medicentro 2004;8(3) Disponible en: http://www.medicentro.sld.cu/index.php/medicentro/article/viewFile/865/875
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology Eur Heart J. 2013 ; 34 (28): 2159-219.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311 (5):507-520.
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15.
Morales Salinas A. Eighth Joint National Committee: otros aspectos polémicos. Finlay. 2014; 4(2) Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/270
Morales Salinas A. El uso de los beta-bloqueadores y el Eighth Joint National Comité. Finlay. 2014; 4(1):75-78 Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/250/1262
Wright JT, Fine LJ, Lackland DT, Ogedegbe G, Cheryl R, Himmelfarb D, et al. Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View. Ann Intern Med. 2014 160(7):499-503
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003
Vanhoutte PM, Gao Y. β-Blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. 2013; 13(2):265-73
Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vas Health Risk Manag. 2011; 7:777-87.
Morales Salinas A. Guidelines for Managing High Blood Pressure JAMA. 2014; 312(3):293-294 Disponible en: http://jama.jamanetwork.com/article.aspx?articleID=1887748&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=MASTER%3AJAMALatestIssueTOCNotification07%2F15%2F2014
Morales Salinas A. Polémica con la utilidad de los beta-bloqueadores en prevención secundaria: análisis crítico del registro REACH. Revista Finlay [revista en Internet]. 2013 [citado 2013 Jun 26]; 3(2):[aprox. 0 p.]. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/189
Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Segunda parte. Finlay. 2012; 2:68-69 Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/97
Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Primera parte. Revista Finlay. 2011;1(2):72-75 Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/47
Morales Salinas A. Los betabloqueadores como primera opción del tratamiento en la hipertensión no complicada: ¿posible o no? Finlay. 2011; 1(1)53-56 Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/27
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
